NCT01154335View on ClinicalTrials.gov

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

OSI-906

Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days

DRUG

Everolimus

Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days

Trial Locations (2)

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

Sponsors
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER